Details of the Drug Combinations

General Information of This Drug (ID: DMU1GX0)

Drug Name
Mitotane   DMU1GX0
Synonyms
Chloditan; Chlodithan; Chlodithane; Khloditan; Khlodithan; Lysodren; Mitotan; Mitotano; Mitotanum; Mytotan; Bristol Myers Squibb Brand of Mitotane; C 3010; CB 313; CB313; PS694_SUPELCO; Bristol-Myers Squibb Brand of Mitotane; CB-313; Lysodren (TN); Mitotano [INN-Spanish]; Mitotanum [INN-Latin]; Ortho,para DDD; Mitotane [USAN:INN:JAN]; O,p-DDD; O,p-Tde; Ortho,para-DDD; Mitotane (JAN/USP/INN); O,p'-DDD; O,p'-Dichlorodiphenyldichloroethane; O,p'-TDE; Ethane, 1,1-dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)-(8CI); (+-)-1,1-Dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)ethane; (2,4'-Dichlorodiphenyl)dichloroethane; (o,p)-DDD; 1,1-Dichloro-2,2-bis(2,4'-dichlorophenyl)ethane; 1,1-Dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)ethane; 1,1-Dichloro-2-(p-chlorophenyl)-2-(o-chlorophenyl)ethane; 1-(2-Chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane; 1-Chloro-2-(2,2-dichloro-1-(4-chlorophenyl)ethyl)benzene; 1-Chloro-2-[2,2-dichloro-1-(4-chlorophenyl)ethyl]benzene; 2,2-Bis(2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane; 2,4'-Ddd; 2,4'-Dichlorodiphenyldichloroethane; 2,4'-Dichlorophenyldichlorethane; 2-(2-Chlorophenyl)-2-(4-chlorophenyl)-1,1-dichloroethane; 2-(o-Chlorophenyl)-2-(p-chlorophenyl)-1,1-dichloroethane
Indication
Disease Entry ICD 11 Status REF
Adrenocortical carcinoma 2D11.Z Approved [1]
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

12 Investigative Drug Combination(s) Consisting of This drug
Normalized Drug Combination Synergy Score
Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
DrugCom Name DrugCom ID Component Drug Indication REF
(-)-englerin A + Mitotane DCICNOQ (-)-englerin A Ewing sarcoma (Cell Line: TC-71) [2]
ABT-263 + Mitotane DCJFJI1 ABT-263 Ewing sarcoma (Cell Line: TC-71) [3]
AT7519 + Mitotane DC1F2RS AT7519 Ewing sarcoma (Cell Line: TC-71) [2]
AZD8055 + Mitotane DC5E6GT AZD8055 Ewing sarcoma (Cell Line: TC-71) [2]
Eltanexor oral + Mitotane DC8N5Z3 Eltanexor oral Ewing sarcoma (Cell Line: TC-71) [2]
Everolimus + Mitotane DCBX0UW Everolimus Ewing sarcoma (Cell Line: TC-71) [2]
GDC-0084 + Mitotane DCWGMAI GDC-0084 Ewing sarcoma (Cell Line: TC-71) [2]
MK-2206 + Mitotane DC3BFP4 MK-2206 Ewing sarcoma (Cell Line: TC-71) [2]
Pelitinib + Mitotane DCTY3BQ Pelitinib Ewing sarcoma (Cell Line: TC-71) [2]
Romidepsin + Mitotane DC2E8HT Romidepsin Ewing sarcoma (Cell Line: TC-71) [2]
TG100801 + Mitotane DCF5P0Q TG100801 Ewing sarcoma (Cell Line: TC-71) [2]
Ym155 + Mitotane DCJ867N Ym155 Ewing sarcoma (Cell Line: TC-71) [2]
------------------------------------------------------------------------------------
⏷ Show the Full List of 12 DrugCom(s)
1 Clinical Trial Drug Combination(s) Consisting of This drug
DrugCom Name DrugCom ID Component Drug Indication REF
Streptozocin + Mitotane DCPJ4NM Streptozocin Carcinoma, Adrenal Cortical [4]
------------------------------------------------------------------------------------

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6957).
2 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
3 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
4 ClinicalTrials.gov (NCT00094497) Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment (FIRM-ACT)